OptiBiotix Health PLC New commercialisation partner in Asia Pacific
OptiBiotix Health PLC
14 September 2022
OptiBiotix Health plc
("OptiBiotix" or the "Company")
New commercialisation partner in Asia Pacific
OptiBiotix Ltd, a wholly owned subsidiary of OptiBiotix Health
plc (AIM: OPTI) and a life sciences business developing patented
science and human study-based compounds that modulate the
microbiome to address a range of health related issues such as
metabolic syndrome and diabetes, systemic low-grade inflammation,
obesity, cardiovascular disease, high cholesterol and healthy aging
announces it has signed a services agreement with Nutraconnect for
the Asia Pacific ("APAC") Region. Nutraconnect will develop and
implement the go-to-market strategy for prebiotics ingredients
SlimBiome (R) and LeanBiome (R) .
Nutraconnect Pte., Ltd. ("Nutraconnect"), is a nutraceutical
business growth acceleration service headquartered in Singapore.
The company provides end-to-end solutions for global nutraceutical
ingredient manufacturers that are looking to establish a foundation
for sustainable growth in the fragmented but growing APAC market.
Nutraconnect possesses a wealth of experience in bringing
innovative and science backed nutraceutical ingredients
successfully to the market in the region.
René Kamminga, C EO of O pti B i oti x Limited, c o mmented : "
Nutraconnect is an important extension of our commercial experience
and reach in the APAC region. Nutraconnect brings unique regulatory
and commercial experience combined with an extensive distribution
and agency network in the various countries in the region. This
partnership will help expedite the commercialisation of our
prebiotic technologies in strategic countries in the region. At the
same time, it will allow OptiBiotix to focus primarily on
established key accounts and building up our North American
presence and sales."
The Directors of the Company are responsible for the release of
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook below
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This communication is a "Reach" announcement. Reach is a
non-regulatory news service. By using this service an issuer is
confirming that the information contained in this announcement is
of a non-regulatory nature. Information required to be notified
under the AIM Rules for Companies, Market Abuse Regulation or other
regulation would be disseminated as an RNS regulatory announcement
and not on RNS Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact firstname.lastname@example.org or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
September 14, 2022 02:02 ET (06:02 GMT)
Grafico Azioni Optibiotix Health (LSE:OPTI)
Da Nov 2022 a Dic 2022
Grafico Azioni Optibiotix Health (LSE:OPTI)
Da Dic 2021 a Dic 2022